Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
46.46
-0.21 (-0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
Next >
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
July 06, 2022
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)...
Via
Benzinga
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
June 30, 2022
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
May 04, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings For Ionis Pharmaceuticals
April 01, 2022
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Via
Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
June 22, 2022
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...
Via
FinancialNewsMedia
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
June 21, 2022
Via
Benzinga
5 Cathie Wood Stocks to Buy in June
June 09, 2022
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments.
Via
InvestorPlace
Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks
March 17, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
February 01, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
June 02, 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Via
InvestorPlace
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
May 20, 2022
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
May 09, 2022
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call
April 25, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
April 04, 2022
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have
Via
Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
March 28, 2022
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.
Via
Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
March 28, 2022
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have
Via
Benzinga
Why Cramer Likes Ferguson And Stanley Black & Decker
March 25, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More
March 11, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
March 02, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More
February 25, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More
February 23, 2022
Benzinga’s Daily Brief On Trending Tickers highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 22, 2022: Tesla, GameStop, Lexicon And More
February 22, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?
February 01, 2022
Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12...
Via
Benzinga
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
January 31, 2022
Currently, analysts expect Moderna sales to drop off after 2022.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.